 Lexaria Bioscience NASDAQ: LEXX, a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXXs patented DehydraTECHTM-processed cannabidiol CBD, demonstrates up to a 23 decrease in blood pressure when compared to placebo. According to the announcement, partial results are being released today with additional blood pressure subset analyses, sleep quality and all other data analyses will be reported when complete. 